Gore Excluder 髂分支内假体治疗主髂动脉瘤的国际多中心前瞻性队列研究一年结果
结果显示12个月一期通畅率为91.3%,30天和12个月免于二次干预率分别为98%和97%,髂总动脉和腹主动脉瘤直径显著减小,临床结局良好。
要点
- 12个月髂内分支一期通畅率为91.3%,免于二次干预率97%。
- 髂总动脉与腹主动脉瘤直径在12个月内显著减小。
- IIEF-5与EQ5D评分保持稳定,对侧髂内动脉通畅与更好的IIEF-5结局相关。
核心结论
- Gore Excluder髂分支内假体治疗主髂动脉瘤12个月内一期通畅率满意,直径显著减小,再干预率低,临床结局良好。
研究设计与样本
- 主要终点为12个月髂内分支一期通畅率;次要终点包括技术与临床结局。
- 收集基线、手术特征、影像、体格检查及问卷(WIQ、EQ5D、IIEF-5)数据至12个月随访。
主要发现
- 42.7%患者腹主动脉瘤超过治疗阈值,其余患者以髂动脉直径作为治疗指征。
- 治疗侧髂总动脉最大直径中位35.5 mm(IQR 30.8-42.0 mm)。
临床怎么用
- 对于主髂动脉瘤需保留髂内动脉灌注的择期患者,Gore Excluder IBE可作为治疗选择,12个月通畅率与再干预率表现良好。
- 术后随访中应关注髂内分支通畅性及动脉瘤直径变化,对侧髂内动脉通畅可能有助于维持性功能相关评分。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: The Gore Excluder Iliac Branch Endoprosthesis (IBE) was developed to preserve perfusion in the hypogastric artery after endovascular repair of aorto-iliac aneurysms. This study reports the 12 month technical and clinical outcomes of treatment with this device. METHODS: This study was a physician initiated international multicentre, prospective cohort study. The primary endpoint was primary patency of the hypogastric branch at 12 months. Secondary endpoints included technical and clinical outcomes. Patients with an indication for elective treatment with the Gore Excluder IBE were enrolled between March 2015 and August 2018. Baseline and procedural characteristics, imaging data, physical examinations and questionnaire data (Walking Impairment Questionnaire [WIQ], EuroQol-5-Dimensions [EQ5D], International Index of Erectile Function 5 [IIEF-5]) were collected through 12 month follow up. RESULTS: One hundred patients were enrolled of which 97% were male, with a median age of 70.0 years (interquartile range [IQR] 64.5 - 75.5 years). An abdominal aortic aneurysm (AAA) above threshold for treatment was found in 42.7% and in the remaining patients the iliac artery diameter was the indication for treatment. The maximum common iliac artery (CIA) diameter on the Gore Excluder IBE treated side was 35.5 mm (IQR 30.8 - 42.0) mm. Twenty-two patients received a bilateral and seven patients had an isolated IBE. Median procedural time was 151 minutes (IQR 117 - 193 minutes) with a median hospital stay of four days (IQR 3 - 5 days). Primary patency of the IBE at 12 month follow up was 91.3%. Primary patency for patients treated inside and outside the instructions for use were 91.8% and 85.7%, respectively (p = .059). Freedom from secondary interventions was 98% and 97% at 30 days and 12 months, respectively. CIA and AAA diameters decreased significantly through 12 months. IIEF-5 and EQ5D scores remained stable through follow up. Patency of the contralateral internal iliac artery led to better IIEF-5 outcomes. WIQ scores decreased at 30 days and returned to baseline values through 12 months. CONCLUSION: Use of the Gore Excluder IBE for the treatment of aorto-iliac aneurysms shows a satisfactory primary patency through 12 months, with significant decrease of diameters, a low re-intervention rate, and favourable clinical outcomes.
引用
- van der Veen D, Holewijn S, Bellosta R, et al. One Year Outcomes of an International Multicentre Prospective Cohort Study on the Gore Excluder Iliac Branch Endoprosthesis for Aorto-Iliac Aneurysms. Eur J Vasc Endovasc Surg. 2021. PMID: 34144884. doi:10.1016/j.ejvs.2021.04.006
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。